Pharma Stocks Crash on Trump Pricing Hints
American drugmakers, who had hoped US President-Elect Donald Trump would go easier on the industry than Hillary Clinton and Bernie Sanders had promised to do, received an unexpected shock on Jan. 11....
View ArticleTrump Discusses Issues With Drugmakers
In a meeting at the White House on Jan. 31, new US president, Donald Trump, held out both a carrot and a stick to pharmaceutical producers. The industry will “have to “get prices down,” he told company...
View ArticlePharma Chiefs Call for Decision on EMA
Pharma chiefs are urging European heads of state to decide sooner rather than later on the new location for the European Medicines Agency (EMA), which is due to leave the UK as a result of Brexit. read...
View ArticleInterest in new Migraine Treatments High
The US Food and Drug Administration‘s (FDA) recent approval of a new migraine treatment marketed by Amgen and Novartis has met with an enthusiastic response since it was greenlighted in May; however,...
View ArticleNovartis and Amgen in Migraine Dispute
Swiss drugmaker Novartis and US biopharma Amgen are embroiled in a legal dispute regarding their collaboration on migraine prevention drug Aimovig. Novartis has filed a complaint in a Manhattan federal...
View ArticleAdvocacy Group Sues FDA Over Dopamine Warnings
The US market watchdog Public Citizen has sued the Food and Drug Administration (FDA), demanding that a district court in Washington, DC, require the agency to add “black box” warnings to six dopamine...
View ArticleAmgen Wins Enbrel Patent Case
The US District Court for the District of New Jersey has upheld two of Amgen’s patents for its top-selling drug Enbrel (etanercept) in a ruling against Sandoz, which has been seeking to launch its...
View ArticleAmgen Makes $13 billion Grab for Otezla
Contrary to recent speculation that Amgen was preparing to buy Alexion, the California-based US biotech has announced that it instead will acquire Celgene’s Otezla, the only oral, non-biologic...
View ArticleAmgen and China’s BeiGene in Oncology Partnership
US biotech Amgen has agreed to take a 20.5% stake in China’s BeiGene as the two companies enter into a strategic collaboration to develop cancer drugs. The move significantly accelerates Amgen’s plans...
View ArticleSanofi's Best Bet Still May Be Smaller Deals
Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying to balance the need...
View Article
